Article Versions Notes

Huang Y-H, Wu Y-H, Tang H-Y, Chen S-T, Wang C-C, Ho W-J, Lin Y-H, Liu G-H, Lin P-Y, Lo C-J, et al. Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study. Pharmaceutics. 2022; 14(9):1857. https://doi.org/10.3390/pharmaceutics14091857

Huang, Yueh-Hsiang, Yi-Hong Wu, Hsiang-Yu Tang, Szu-Tah Chen, Chih-Ching Wang, Wan-Jing Ho, Yi-Hsuan Lin, Geng-Hao Liu, Pei-Yeh Lin, Chi-Jen Lo, and et al. 2022. "Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study" Pharmaceutics 14, no. 9: 1857. https://doi.org/10.3390/pharmaceutics14091857

Huang, Y.-H., Wu, Y.-H., Tang, H.-Y., Chen, S.-T., Wang, C.-C., Ho, W.-J., Lin, Y.-H., Liu, G.-H., Lin, P.-Y., Lo, C.-J., Yeh, Y.-M., & Cheng, M.-L. (2022). Gut Microbiota and Bile Acids Mediate the Clinical Benefits of YH1 in Male Patients with Type 2 Diabetes Mellitus: A Pilot Observational Study. Pharmaceutics, 14(9), 1857. https://doi.org/10.3390/pharmaceutics14091857